✦ LIBER ✦

A Phase I Trial of Bexarotene in Combination With Docetaxel in Patients With Advanced Solid Tumors

✍ Scribed by Shakun M. Malik; Brian Collins; Michael Pishvaian; Pari Ramzi; John Marshall; Jimmy Hwang

Book ID: 113544745
Publisher: CIG Media Group, LP.
Year: 2011
Tongue: English
Weight: 805 KB
Volume: 12
Category: Article
ISSN: 1525-7304
DOI: 10.1016/j.cllc.2011.03.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of oxaliplatin in combin

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

✍ Syma Iqbal, Heinz-Josef Lenz, David R. Gandara… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 228 KB

Gemcitabine and Docetaxel in patients wi

Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial

✍ Jaremtchuk, A.V.; Zabra, J.J.; Ferro, A.; Aman, E.F.; Alvarez, R.; Arroyo, G.; M 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Bortezomib in combination with celecoxib

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

✍ John Hayslip; Uzair Chaudhary; Mark Green; Mario Meyer; Steven Dunder; Carol She 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 216 KB

Sunitinib in combination with docetaxel

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

✍ Francisco Robert; Alan Sandler; Joan H. Schiller; Glenn Liu; Karen Harper; Lev V 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 233 KB

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi